Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 426 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Taking Control – Risks vs. Benefits July 14, 2020 5-Year-Old Boy Battling Cancer Receives Dream Come True, Sworn In As... March 24, 2021 Estimate of the Global Economic Cost of the Most Prevalent Cancers... March 13, 2023 Adjuvant Chemotherapy Customisation Based on ERCC1 and TS mRNA Levels Does... October 6, 2021 Load more HOT NEWS After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms Motixafortide May Improve Stem Cell Transplants for People with Multiple Myeloma Metformin May Affect Risk of Breast Cancer in Women with Type... What to Know About Getting Access to New Cancer Advances Presented...
